GGrantIndex
← Leaderboards

Matthew H Wilson

Veterans Health Administration

$7,020,154
Attributed
$7,690,084
Total exposure
7
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.8M · FY201225
$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$7,690,084 · 5
VA$0 · 2

By mechanism

R01$6,692,994 · 4
P30$997,090 · 1
I01$0 · 2

Top collaborators

Others in their field

Top investigators on “Kidney

Research focus

KidneyAffectIn VivoInnovationMediatingCellsMouse ModelKidney DiseasesGene TransferAnimalsEngineeringIn VitroAnimal ModelSiteGeneticProteinsChronic Kidney FailureMorbidity - Disease RateGrantGene DeliveryTechnologyExperimental DesignsChronicResponse

Grant awards (33)

Kidney targeted AAV for gene therapy$859,980
R01 · FY2025 · DK · contact PI
Next generation transposon vectors for genome engineering$491,492
R01 · FY2025 · EB · contact PI
Beyond Urea Kinetics: Balancing Tradeoffs in Dialyzer Design for the Next 50 Years$479,880
R01 · FY2025 · DK · contact PI
Genome engineering therapeutics for cystinuria and its metabolic consequences.$0
I01 · FY2025 · VA · contact PI
Next generation transposon vectors for genome engineering$481,663
R01 · FY2024 · EB · contact PI
Genome engineering therapeutics for cystinuria and its metabolic consequences.$0
I01 · FY2024 · VA · contact PI
Next generation transposon vectors for genome engineering$491,492
R01 · FY2023 · EB · contact PI
Genome engineering therapeutics for cystinuria and its metabolic consequences.$0
I01 · FY2023 · VA · contact PI
Next generation transposon vectors for genome engineering$525,492
R01 · FY2022 · EB · contact PI
Novel cell therapy for sustained therapeutic protein delivery in vivo$416,707
R01 · FY2022 · DK · contact PI
Novel cell therapy for sustained therapeutic protein delivery in vivo$416,707
R01 · FY2021 · DK · contact PI
Pilot and Feasibility Program$199,418
P30 · FY2021 · DK · contact PI
Metabolic consequences of cystinuria and genome engineering therapeutics$0
I01 · FY2021 · VA · contact PI
Novel cell therapy for sustained therapeutic protein delivery in vivo$416,708
R01 · FY2020 · DK · contact PI
Pilot and Feasibility Program$199,418
P30 · FY2020 · DK · contact PI
Metabolic consequences of cystinuria and genome engineering therapeutics$0
I01 · FY2020 · VA · contact PI
Novel cell therapy for sustained therapeutic protein delivery in vivo$416,707
R01 · FY2019 · DK · contact PI
Pilot and Feasibility Program$199,418
P30 · FY2019 · DK · contact PI
Metabolic consequences of cystinuria and genome engineering therapeutics$0
I01 · FY2019 · VA · contact PI
Pilot and Feasibility Program$199,418
P30 · FY2018 · DK · contact PI
Metabolic consequences of cystinuria and genome engineering therapeutics$0
I01 · FY2018 · VA · contact PI
Pilot and Feasibility Program$199,418
P30 · FY2017 · DK · contact PI
Kidney specific site-directed integration for cystinuria$0
I01 · FY2017 · VA · contact PI
Novel cell therapy for anemia of CKD$343,650
R01 · FY2016 · DK · contact PI
Kidney specific site-directed integration for cystinuria$0
I01 · FY2016 · VA · contact PI
Novel cell therapy for anemia of CKD$230,834
R01 · FY2015 · DK · contact PI
Novel cell therapy for anemia of CKD$111,346
R01 · FY2015 · DK · contact PI
Kidney specific site-directed integration for cystinuria$0
I01 · FY2015 · VA · contact PI
Novel cell therapy for anemia of CKD$341,475
R01 · FY2014 · DK · contact PI
Kidney specific site-directed integration for cystinuria$0
I01 · FY2014 · VA · contact PI
Novel cell therapy for anemia of CKD$327,204
R01 · FY2013 · DK · contact PI
Novel cell therapy for anemia of CKD$1,269
R01 · FY2013 · DK · contact PI
Novel cell therapy for anemia of CKD$340,388
R01 · FY2012 · DK · contact PI